HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Acute myeloid leukaemia with RBM15::MRTFA fusion}} | {{DISPLAYTITLE:Acute myeloid leukaemia with RBM15::MRTFA fusion}} | ||
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | ||
| Line 28: | Line 27: | ||
|} | |} | ||
==Related Terminology== | ==Related Terminology== | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
|Acceptable | |Acceptable | ||
| | |Acute megakaryoblastic leukaemia with RBM15::MRTFA | ||
|- | |- | ||
|Not Recommended | |Not Recommended | ||
| | |Acute myeloid leukaemia with RBM15::MKL1; acute megakaryoblastic leukaemia with RBM15::MKL1; acute myeloid leukaemia with OTT::MAL | ||
|} | |} | ||
| Line 62: | Line 48: | ||
|- | |- | ||
|''RBM15'' and ''MKL1'' | |''RBM15'' and ''MKL1'' | ||
|''RBM15''(''OTT'')::''MKL1''(''MAL'')||The majority of both genes retained in the fusion 5’ ''DEK'' and 3’''NUP214''(''CAN'') with the pathogenic derivative being | |''RBM15''(''OTT'')::''MKL1''(''MAL'')||The majority of both genes are retained in the fusion, specifically 5’ ''DEK'' and 3’''NUP214''(''CAN''), with the pathogenic derivative being the der(22).||t(1;22)(p13.3;q13.1) | ||
|Rare (AML) | |Rare (AML) | ||
|D | |D | ||
| Line 77: | Line 63: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Chr #!! | !Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s) | ||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|N/A | |N/A | ||
| Line 95: | Line 81: | ||
!Chromosomal Pattern | !Chromosomal Pattern | ||
!Molecular Pathogenesis | !Molecular Pathogenesis | ||
! | !Prevalence - | ||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|N/A | |N/A | ||
| Line 110: | Line 96: | ||
==Gene Mutations (SNV/INDEL)== | ==Gene Mutations (SNV/INDEL)== | ||
COSMIC does not have specific information on mutations related to this subtype of AML. | *COSMIC does not have specific information on mutations related to this subtype of AML. | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Gene!! | !Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence - | ||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|N/A | |N/A | ||
| Line 133: | Line 120: | ||
==Genes and Main Pathways Involved== | ==Genes and Main Pathways Involved== | ||
The molecular mechanism is not completely understood, but the fusion protein may modulate chromatin organization, HOX-induced differentiation and extracellular signaling pathways associated with leukemogenesis<ref>{{Cite journal|last=Mercher|first=T.|last2=Coniat|first2=M. B.|last3=Monni|first3=R.|last4=Mauchauffe|first4=M.|last5=Nguyen Khac|first5=F.|last6=Gressin|first6=L.|last7=Mugneret|first7=F.|last8=Leblanc|first8=T.|last9=Dastugue|first9=N.|date=2001-05-08|title=Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/11344311|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=98|issue=10|pages=5776–5779|doi=10.1073/pnas.101001498|issn=0027-8424|pmc=33289|pmid=11344311}}</ref>. The fusion of MKL1 to RBM15 deregulates the normal intracellular localization of MKL1 such that it is becomes constitutively localized to the nucleus, resulting in serum response factor (SRF) activation even in the absence of stimuli<ref>{{Cite journal|last=Gruber|first=Tanja A.|last2=Downing|first2=James R.|date=2015-08-20|title=The biology of pediatric acute megakaryoblastic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/26186939|journal=Blood|volume=126|issue=8|pages=943–949|doi=10.1182/blood-2015-05-567859|issn=1528-0020|pmc=4551356|pmid=26186939}}</ref>. SRF is a transcription factor that regulates the expression of genes involved in cell growth, proliferation, and differentiation, as well as genes that control the actin cytoskeleton<ref>{{Cite journal|last=Halene|first=Stephanie|last2=Gao|first2=Yuan|last3=Hahn|first3=Katherine|last4=Massaro|first4=Stephanie|last5=Italiano|first5=Joseph E.|last6=Schulz|first6=Vincent|last7=Lin|first7=Sharon|last8=Kupfer|first8=Gary M.|last9=Krause|first9=Diane S.|date=2010-09-16|title=Serum response factor is an essential transcription factor in megakaryocytic maturation|url=https://pubmed.ncbi.nlm.nih.gov/20525922|journal=Blood|volume=116|issue=11|pages=1942–1950|doi=10.1182/blood-2010-01-261743|issn=1528-0020|pmc=3173990|pmid=20525922}}</ref>. Of note, while a ''RBM15''::''MKL1'' fusion knock-in model mouse | *The molecular mechanism is not completely understood, but the fusion protein may modulate chromatin organization, HOX-induced differentiation and extracellular signaling pathways associated with leukemogenesis<ref>{{Cite journal|last=Mercher|first=T.|last2=Coniat|first2=M. B.|last3=Monni|first3=R.|last4=Mauchauffe|first4=M.|last5=Nguyen Khac|first5=F.|last6=Gressin|first6=L.|last7=Mugneret|first7=F.|last8=Leblanc|first8=T.|last9=Dastugue|first9=N.|date=2001-05-08|title=Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/11344311|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=98|issue=10|pages=5776–5779|doi=10.1073/pnas.101001498|issn=0027-8424|pmc=33289|pmid=11344311}}</ref>. The fusion of MKL1 to RBM15 deregulates the normal intracellular localization of MKL1 such that it is becomes constitutively localized to the nucleus, resulting in serum response factor (SRF) activation even in the absence of stimuli<ref>{{Cite journal|last=Gruber|first=Tanja A.|last2=Downing|first2=James R.|date=2015-08-20|title=The biology of pediatric acute megakaryoblastic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/26186939|journal=Blood|volume=126|issue=8|pages=943–949|doi=10.1182/blood-2015-05-567859|issn=1528-0020|pmc=4551356|pmid=26186939}}</ref>. SRF is a transcription factor that regulates the expression of genes involved in cell growth, proliferation, and differentiation, as well as genes that control the actin cytoskeleton<ref>{{Cite journal|last=Halene|first=Stephanie|last2=Gao|first2=Yuan|last3=Hahn|first3=Katherine|last4=Massaro|first4=Stephanie|last5=Italiano|first5=Joseph E.|last6=Schulz|first6=Vincent|last7=Lin|first7=Sharon|last8=Kupfer|first8=Gary M.|last9=Krause|first9=Diane S.|date=2010-09-16|title=Serum response factor is an essential transcription factor in megakaryocytic maturation|url=https://pubmed.ncbi.nlm.nih.gov/20525922|journal=Blood|volume=116|issue=11|pages=1942–1950|doi=10.1182/blood-2010-01-261743|issn=1528-0020|pmc=3173990|pmid=20525922}}</ref>. Of note, while a ''RBM15''::''MKL1'' fusion knock-in model mouse showed abnormal megakaryopoiesis, it was not sufficient to induce leukemia<ref>{{Cite journal|last=Mercher|first=Thomas|last2=Raffel|first2=Glen D.|last3=Moore|first3=Sandra A.|last4=Cornejo|first4=Melanie G.|last5=Baudry-Bluteau|first5=Dominique|last6=Cagnard|first6=Nicolas|last7=Jesneck|first7=Jonathan L.|last8=Pikman|first8=Yana|last9=Cullen|first9=Dana|date=2009-04|title=The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model|url=https://pubmed.ncbi.nlm.nih.gov/19287095|journal=The Journal of Clinical Investigation|volume=119|issue=4|pages=852–864|doi=10.1172/JCI35901|issn=1558-8238|pmc=2662544|pmid=19287095}}</ref>. | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| Line 139: | Line 127: | ||
|- | |- | ||
|''RBM15'' and ''MKL1''; Gain-of-function | |''RBM15'' and ''MKL1''; Gain-of-function | ||
|HOX signaling | |HOX and other signaling pathways | ||
| | |Abnormal megakaryopoiesis | ||
|} | |} | ||
==Genetic Diagnostic Testing Methods== | ==Genetic Diagnostic Testing Methods== | ||
Karyotype, FISH, RT-PCR | Karyotype, FISH, RT-PCR (and any other fusion detecting technologies) | ||
==Familial Forms== | ==Familial Forms== | ||
| Line 161: | Line 149: | ||
==References== | ==References== | ||
<references /> | |||
<br /> | <br /> | ||